Spyre Therapeutics (SYRE) CFO sells 7,500 shares after exercising stock options
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Spyre Therapeutics (SYRE) Chief Financial Officer Scott L. Burrows exercised stock options and sold shares in a pre-planned transaction. On June 1, 2026, he exercised options to acquire 7,500 shares of common stock at $14.50 per share and sold 7,500 shares in three open-market trades at weighted-average prices around the low $70s, pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. After these transactions, he directly holds 105,494 shares of common stock, including 67,476 restricted stock units that vest in equal installments in 2026 and 2027, and continues to hold a large stock option covering hundreds of thousands of additional shares.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 7,500 shares ($532,937)
Net Sell
5 txns
Insider
Burrows Scott L
Role
Chief Financial Officer
Sold
7,500 shs ($533K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 7,500 | $0.00 | -- |
| Exercise | Common Stock | 7,500 | $14.50 | $109K |
| Sale | Common Stock | 1,801 | $69.75 | $126K |
| Sale | Common Stock | 2,599 | $70.77 | $184K |
| Sale | Common Stock | 3,100 | $72.06 | $223K |
Holdings After Transaction:
Stock Option (Right to Buy) — 374,857 shares (Direct, null);
Common Stock — 105,494 shares (Direct, null)
Footnotes (1)
- This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $69.37 to $70.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $70.38 to $71.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $71.54 to $72.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Includes 67,476 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock. The RSUs vest in two equal installments on each of September 1, 2026 and 2027, subject to the Reporting Person's continued employment with the Issuer. This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.
Key Figures
Shares sold: 7,500 shares
Sale prices: $69.75, $70.77, $72.06 per share
Options exercised: 7,500 shares at $14.50/share
+4 more
7 metrics
Shares sold
7,500 shares
Common stock sold in three open-market trades on June 1, 2026
Sale prices
$69.75, $70.77, $72.06 per share
Weighted-average prices for three sale blocks of common stock
Options exercised
7,500 shares at $14.50/share
Stock option exercise converting into common shares on June 1, 2026
Post-transaction holdings
105,494 shares
Common stock directly held after transactions, including RSUs
Restricted stock units
67,476 RSUs
Vesting in two equal installments on September 1, 2026 and 2027
Options remaining
374,857 options
Stock options following the 7,500-share exercise; expire September 1, 2033
Total option grant size
404,857 shares
Original option size adjusted for 1-for-25 reverse stock split
Key Terms
Rule 10b5-1 trading plan, restricted stock units ("RSUs"), weighted average price, reverse stock split, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
restricted stock units ("RSUs") financial
"Includes 67,476 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
weighted average price financial
"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $69.37 to $70.36, inclusive."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
reverse stock split financial
"This option represents a right to purchase 404,857 shares ... which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023."
A reverse stock split is when a company reduces the number of its shares outstanding, making each share more valuable. For example, if you own 100 shares worth $1 each, a 1-for-10 reverse split would turn your 100 shares into 10 shares worth $10 each. Companies often do this to boost their stock price and appear more stable to investors.
stock option (Right to Buy) financial
"Stock Option (Right to Buy) ... This option represents a right to purchase 404,857 shares of the Issuer's common stock"
FAQ
What insider transactions did Spyre Therapeutics (SYRE) CFO Scott Burrows report?
Scott Burrows reported exercising options for 7,500 Spyre Therapeutics shares at $14.50 each and selling 7,500 common shares in three open-market trades at prices around $69.75 to $72.06, all executed on June 1, 2026.
What are the vesting terms for the SYRE CFO’s restricted stock units?
The filing notes 67,476 restricted stock units for the CFO. Each RSU represents one Spyre Therapeutics share upon vesting. These units vest in two equal installments on September 1, 2026 and September 1, 2027, contingent on his continued employment with the company.